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Strengths and limitations of this study
 ► This is a randomised controlled trial with an ade-
quate sample size to evaluate in vitro maturation 
(IVM) treatment in infertile women with polycystic 
ovary syndrome.
 ► This study will provide evidence on whether the ex-
perimental group (IVM) is non- inferior to the stan-
dard in vitro fertilisation in terms of live birth.
 ► The cost- effective analysis is not included in the 
study, limiting the comprehensiveness of the results.
AbStrACt
Introduction Polycystic ovary syndrome (PCOS) is the 
first common cause of anovulatory infertility. Currently, in 
vitro fertilisation (IVF) is recommended when conventional 
attempts have failed. In vitro maturation (IVM) of human 
oocytes is an emerging treatment option in infertile women 
with PCOS. It is a patient- friendly intervention, avoiding 
the risk of ovarian hyperstimulation syndrome, which is 
a serious complication of controlled ovarian stimulation 
in the standard IVF procedure. We plan a randomised 
controlled trial (RCT) to evaluate whether IVM is non- 
inferior to the standard IVF for live birth in women with 
PCOS.
Methods and analysis This is a single- centre, open- 
label, non- inferiority RCT performed in a large reproductive 
medicine centre in China. Infertile women with PCOS will 
be randomised to receive either IVM or standard IVF in a 
1:1 treatment ratio after informed consent. IVF procedures 
used in our study are all standard treatments and other 
standard- assisted reproductive technologies will be similar 
between the two groups. The primary outcome is ongoing 
pregnancy leading to live birth within 6 months of the 
first oocyte retrieval cycle after randomisation. Pregnancy 
outcome, maternal safety and obstetric and perinatal 
complications will be secondary outcomes. The planned 
sample size is 350 (175 per group).
Ethics and dissemination Ethical permission was 
acquired from the Ethics Committee of Peking University 
Third Hospital. The results will be issued to publications 
through scientific journals and conference reports.
trial registration number NCT03463772.
IntroduCtIon
Polycystic ovary syndrome (PCOS) is the first 
common cause of anovulatory infertility and 
occurs in 5.6% in reproductive- aged women 
in the Chinese communities1. It is also a major 
metabolic disorder associated with insulin 
resistance, β-cell dysfunction and obesity.2 
Fifty per cent of women with PCOS present 
with subfertility. In anovulatory women with 
PCOS, the first- line treatments are lifestyle 
intervention and ovulation induction with 
letrozole or clomiphene citrate.3 Laparo-
scopic ovarian drilling or ovarian induction 
with gonadotrophin (Gn) is considered as the 
second- line treatment options. In vitro fertil-
isation (IVF) is the third- line treatment and 
is recommended when the above- mentioned 
treatments have failed.
In standard IVF treatment, women with 
PCOS are at high risk of ovarian hyperstim-
ulation syndrome (OHSS), which is a serious 
and common iatrogenic complication of 
controlled ovarian stimulation (COS). The 
prevalence of moderate and severe forms of 
OHSS in women undergoing IVF is 3%–8% 
and much higher in women with PCOS.4 
Severe OHSS is defined by the presence 
of clinical evidence of ascites with severe 
abdominal pain and pleural effusion. A large 
amount of pleural and peritoneal effusion 
can lead to intravascular blood loss, blood 
concentration, blood hypercoagulability, 
hypovolemic shock, severe cardiopulmonary 
dysfunction, electrolyte imbalance, impaired 
liver and kidney function, thrombosis and 
even life- threatening.5 Therefore, seeking an 
alternative treatment strategy, avoiding the 
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risk of OHSS without compromising pregnancy outcomes 
is crucial for women with PCOS.
In vitro maturation (IVM) has been introduced in 
1990. Trounson et al6 described the first delivery of a 
healthy baby with the IVM technique in a woman with 
PCOS. From then on, immature oocyte retrieval followed 
by IVM had been used widely, resulting in the delivery of 
thousands of healthy infants worldwide.7–9 In IVM, imma-
ture oocytes are collected from antral follicles, typically 
from unstimulated or minimally stimulated ovaries, then 
cultured, matured and fertilised in vitro.10 Compared 
with standard IVF treatment, IVM is performed without 
ovarian stimulation, thus preventing the occurrence of 
OHSS and reducing financial costs.
To date, despite the publication of many studies on 
IVM, the effectiveness and safety of IVM treatment are 
still controversial. Some studies showed that the live birth 
rate was significantly lower in the IVM group than in the 
IVF group.11–13 Now mature technology, gradually getting 
more research results, indicated comparable pregnancy 
outcomes between IVM and IVF group.14 15 Until now, all 
data available have derived from observational studies.16 
Given the unique advantages of IVM as safer, simpler and 
cheaper,17 we need further evidence from well- designed 
randomised controlled trials (RCTs) on the live birth 
rate before we draw conclusions on the effectiveness and 
safety of IVM. Therefore, we plan an RCT to determine 
whether IVM is non- inferior to standard IVF on live birth 
for women with PCOS.
MEthodS And AnAlySIS
Study design
This is a single- centre, non- inferiority RCT with a 1:1 
treatment ratio. The programme for enrolment, inter-
ventions and evaluation during the study process is 
shown in table 1. Figure 1 indicates a flowchart showing 
the registration, allocation, treatment and follow- up of 
participants.
Study setting
The trial is approved by the Ethics Committee of Peking 
University Third Hospital (2017sz-066). Women with 
PCOS and infertility who scheduled for their first IVF 
attempt at Peking University Third Hospital (Beijing, 
China) will be recruited. Potentially eligible women will 
be given information about the study during their first 
consultation. All the couples provided written informed 
consent before participation. The trial progress will be 
monitored by an independent data and safety monitoring 
board (DSMB).
Eligibility criteria
PCOS outpatient women with infertility who come to the 
reproductive centre of Peking University Third Hospital 
will be screened for eligibility by a research team.
Inclusion criteria
 ► Married Chinese women with infertility aged between 
20 and 38 years.
 ► Women with PCOS according to the revised 
Rotterdam criteria (ie, two of the three following 
features are present: (1) oligo and/or anovulation; 
(2) clinical and/or biochemical signs of hyperan-
drogenism; and (3) polycystic ovaries). Exclusion of 
other possible related disorders: ovarian or adrenal 
androgen- secreting tumours, thyroid disease, 
hyperprolactinaemia, and non- classical adrenal 
hyperplasia.18
 ► Women scheduled for their first IVF/intracyto-
plasmic sperm injection (ICSI) cycle. Women must 
have an indication for assisted reproductive tech-
nology (ART), including ovulation dysfunction and 
failure to become pregnant after ovulation induc-
tion treatment; unilateral or bilateral tubal obstruc-
tion, adhesion, salpingectomy or tubal ligation; and 
oligoasthenozoospermia.
 ► Written informed consent obtained.
Exclusion criteria
 ► Couples with a contraindication for IVF or ICSI 
(including but not limited to poorly controlled type 
1 or type 2 diabetes mellitus; liver disease or dysfunc-
tion (based on serum liver enzyme test results); renal 
disease or abnormal serum renal function; anaemia; 
history of deep venous thrombosis, pulmonary 
embolus or cerebrovascular accident; uncontrolled 
hypertension or known symptomatic heart disease; 
history of (or suspected) cervical carcinoma, endome-
trial carcinoma or breast carcinoma; and unexplained 
colporrhagia).
 ► Couples receiving donor sperm or donor oocytes.
 ► Couples with indications or have the plan to receive 
preimplantation genetic testing.
 ► Women with a male partner diagnosed with 
azoospermia.
 ► Either a male partner or female partner with a known 
abnormal chromosome karyotype (chromosome poly-
morphisms were not included).
 ► Women who have undergone unilateral ovariectomy.
Participants can leave the study at any time without any 
consequences for their clinical treatments.
recruitment
Potentially eligible women will be informed about the 
trial during their first consultation. If a woman wants to 
participate, written informed consent will be acquired in 
their next scheduled visit. To initiate the IVM or IVF treat-
ment cycle in anovulatory cases, patients were adminis-
trated oral dydrogesterone (Duphaston, Abbott, OLST, 
Netherlands) 20 mg daily for 10–14 days/oral contracep-
tives Diane-35 (cyproterone acetate 2 mg, ethinylestra-
diol 35 mg, Bayer and its generics) for 21 days. After the 
withdrawal bleeding, eligible participants will be assessed 
again for the exclusion criteria on day 2 or day 3 following 
the onset of menstrual bleeding.
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Figure 1 Flowchart of this randomised controlled trial: IVM 
versus IVF in women with polycystic ovary syndrome. COS, 
controlled ovarian stimulation; IVF, in vitro fertilisation; IVM, in 
vitro maturation.
randomisation and allocation concealment
Randomisation and allocation of qualified participants 
will be done on day 2/3 of the menstrual cycle. Eligible 
participants will be allocated to IVM or IVF treatment 
according to a computer- generated randomisation list in 
a 1:1 ratio, with a variable block size of 4 or 6. Opaque- 
sealed envelopes, with participant’s screening order 
printed outside and randomised- assigned group printed 
inside, will be numbered consecutively. Researchers will 
enrol the eligible participants after the screening, then 
open each envelope in a sequence corresponding with 
the screening order and assign the participant into the 
IVM or IVF group. Both investigators and participants will 
be aware of the allocation of the subsequent treatments.
Interventions
IVM protocol
Gns (follicle stimulating hormone (FSH), HMG or 
human chorionic Gn (hCG)) will not be used in the IVM 
group. After randomisation, participants will visit the 
clinic on days 6–8 for a transvaginal ultrasound examina-
tion to exclude the development of a dominant follicle. 
Oocyte retrieval will be scheduled once the endometrium 
thickness reaches at least 6 mm and there is no appear-
ance of the dominant follicle (follicle diameter >10 mm). 
Transvaginal ultrasound- guided oocytes retrieval will be 
conducted with a single- lumen 19G aspiration needle 
(K- OPS-7035- REH- ET; Cook, Queensland, Australia) in 
90 mm Hg suction pressure. Follicular aspirates will be 
gathered and filtered through a cell strainer (Cell Strainer 
352350, 70 µm nylon; Falcon, Massachusetts, USA). Then 
the collected aspirates will be washed with prewarmed 
Hepe’s- HTF (CooperSurgical; Trumbull, Connecticut, 
USA). The mixture will be examined carefully under 
a stereomicroscope to search for cumulus- oocyte 
complexes (COCs). All COCs will be transferred into 
IVM medium (IVM media kit; Sage, Connecticut, USA) 
supplemented with 0.075 IU/mL FSH and 0.075 IU/mL 
LH (Menopur; Ferring, Kiel, Germany) in 5% CO2 incu-
bator at 37°C. All the COCs will be denuded of cumulus 
cells after 28–32 hours of culture and evaluated the matu-
ration process. The presence of a first polar body indi-
cates that the oocyte enters the metaphase II stage. All the 
metaphase II (MII) oocytes will be inseminated by means 
of intracytoplasmic sperm injection (ICSI).
IVF protocol
For participants in the IVF group, COS will be performed 
by a flexible protocol using Gn- releasing hormone antag-
onist (GnRH- ant) with recombinant FSH (rFSH) and 
recombinant human chorionic Gn (rhCG). Treatment 
will start on day 2/3 of the menstrual cycle. All partic-
ipants will be subcutaneous injected rFSH (Gonal- F; 
Serono, Geneva, Switzerland) with 100–225 IU/day 
initial dosage. Transvaginal ultrasound, serum luteinising 
hormone (LH), serum oestrogen (E2) and progesterone 
(P4) will be tested to monitor follicle growth. rFSH doses 
will be adjusted according to ovarian response. GnRH 
antagonist- cetrorelix (Cetrotide; Serono, Darmstadt, 
Germany) 0.25 mg daily by subcutaneous injection will 
begin when at least one follicle has reached a diameter 
of 12 mm which is usually between day 5 and day 8 of 
ovarian stimulation, until the trigger day (include the 
trigger day). After two or more follicles reach a diameter 
≥17 mm, 250 µg of rhCG (Ovidrel; Serono, Aubonne, 
Germany) will be once injected on trigger day. Oocyte 
retrieval will be performed 36 (±2) hours after rhCG 
injection. Oocyte collection is conducted via 17G oocyte 
aspiration needle with the use of intravenous sedation. All 
COCs will be cultured in human tubal fluid medium and 
incubated in a humidified 37°C incubator 5% CO2, after 
oocyte retrieval immediately. The fertilisation method 
will be selected according to the semen analysis.
Assessment of fertilisation and embryo culture
Fertilisation will be considered normal when two pronu-
clei are present between 16 and 18 hours after ICSI or 
IVF. Normal fertilisation rate will be calculated as the 
number 2PN over the number of MII in ICSI patients 
or the number 2PN over the number of COCs for 
conventional IVF. All zygotes will be cultured in cleavage 
medium (G- 1plus, Vitrolife, USA) for further 48–52 hour 
after fertilisation. Cleavage embryonic development will 
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be assessed according to the developmental stage and 
degree of cytoplasmic fragmentation. All day 3 embryos 
will be cultured up to 2–3 days (G-2 plus, Vitrolife, USA). 
From day 5 to day 6, those embryos achieving the blasto-
cyst stage will be evaluated morphologically using Gard-
ner’s grading system.
For all participants, a freeze- only blastocyst transfer 
strategy will be applied. All usable blastocysts (embryos 
that can grow to expanded or hatching blastocysts earn a 
score above grade CC) will be cryopreserved by vitrifica-
tion methods.
Blastocyst vitrification and warm
The expanded blastocysts collapsed after artificial 
shrinkage will be vitrified and warmed as previously 
demonstrated.19 In brief, the blastocysts will be trans-
ferred in equilibration medium, which included 7.5% 
(v/v) dimethyl sulfoxide (DMSO, Sigma Chemical Co., 
Missouri, USA) and 7.5% (v/v) ethylene glycol (EG, 
Sigma Chemical Co), at 37°C for 2 min, then placed in 
vitrification solution for 30 s that containing 15% DMSO, 
15% EG and 0.65 mol/L sucrose. During this period, 
shrinkage blastocyst will be loaded on the cryotop strip 
(Kitazato, Fuji, Japan), next plunged into liquid nitrogen 
immediately. For warming, the cryotop will be quickly 
placed in 0.33 mol/L sucrose at 37°C and searching for 
the floated blastocyst under the microscope. The blas-
tocyst will be washed several times and placed for 2 min. 
Then it will be transferred into 0.2 mol/L sucrose for 
3 min and in a N-2- hydroxyethylpiperazine- N- ethane- 
sulphonicacid (HEPES)- buffered medium for 5 min in 
turn. After 2 hours, the blastocysts will be evaluated the 
quality. The re- expanded blastocysts will be considered to 
survive and will be transferred to the patients.
Endometrium preparation, blastocyst transfer and luteal support
In vitrified- warmed blastocyst transferred cycles, partici-
pants will undergo hormone replacement therapy (HRT) 
for their endometrial preparation. All participants’ once 
endometrial thickness reaches 6 mm and no ovarian cyst 
is observed on ultrasound, oral oestradiol valerate (Prog-
ynova, Delpharm Lille, Lys- Lez- Lannoy, France) at a 
dose of 3 mg two times per day will be started on day 1–3 
of the menstrual cycle. And then an ultrasound will be 
repeated after more than 10 days after administration of 
HRT, vaginal progesterone gel (Crinone, Merck Serono, 
Watford, UK) 90 mg per day and oral dydrogesterone 
(Duphaston, Abbott) 20 mg two times per day will be 
added when the endometrial thickness was ≥8 mm. All the 
ultrasound scans and measurements will be performed 
with the digital platform Voluson E8 system. Only one 
blastocyst will be transferred on day 7 after progesterone 
administration. Luteal phase support was continued until 
12 weeks gestation.
Follow-up
All participants will measure the hCG of urine and blood 
at the 12 days after blastocyst transfer, in which positive 
results indicate biochemical pregnancy. On 28 days after 
transfer, if the gestational sac is observed with ultrasonog-
raphy, participants will be diagnosed with clinical preg-
nancy. Ongoing pregnancy is defined as a sac with the 
fetal heartbeat and occurs after 12 weeks of pregnancy. 
Ongoing pregnancy leading to live birth is defined by 
the live fetus in the uterine after 22 weeks of gestation. 
We will collect the following information within 6 weeks 
after delivery, prenatal testing information (pregnancy 
complications and fetal information), delivery informa-
tion (gestational age, mode of delivery, placental condi-
tion and birth complications) and newborn information 
(fetal sex, birth weight and birth defects).
outcome measures
Primary outcome
Our primary study endpoint is ongoing pregnancy leading 
to live birth (gestation age ≥22 weeks) within 6 months of 
the first oocyte retrieval cycle after randomisation.20
Secondary outcomes
Secondary outcomes of our trial include pregnancy 
outcomes, maternal safety and obstetric and peri-
natal complications. Detailed information is provided 
in table 2. Maternal safety is an important part of the 
secondary outcomes. The incidence of OHSS is the key 
indicator of maternal safety. Routine evaluation for OHSS 
will be performed on oocyte retrieval day and on day 3 
after fertilisation with ultrasound scanning and hormonal 
result in all participants. It is classified as mild, moderate 
or severe according to the Royal College of Obstetricians 
& Gynaecologists guildline.21
Safety reporting
Adverse events (AE) are defined as any undesirable expe-
rience occurring to a subject during the trial. A serious 
AE (SAE) is any untoward medical events, that results 
in death; is life- threatening (at the time of the event); 
requires hospitalisation or prolongation of existing inpa-
tients’ hospitalisation; results in persistent or significant 
disability or incapacity; is a congenital anomaly or birth 
defect; and is a new event of the trial likely to affect the 
safety of the subjects, such as an unexpected outcome of 
an adverse reaction.
SAE in this study includes: moderate/severe OHSS; 
intraperitoneal haemorrhage or ovarian torsion after 
oocyte retrieval; ectopic pregnancy; severe pre- eclampsia; 
pregnancy complications leading to hospitalisation; still-
birth; birth defects; other serious medical events judged 
by researchers to meet the criteria of SAE.
All SAEs will be reported to the DSMB and accredited 
Medical Education Technology Committee (METC) that 
approved the protocol, according to the requirements of 
that METC.
Statistical analysis
Sample size calculation
The primary hypothesis of this study is that the experi-
mental group (IVM) is non- inferior to the control group 
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Table 2 Secondary outcomes and related definition
Secondary outcomes Definition
Pregnancy outcomes
  Implantation Number of gestational sacs observed per embryo transferred
  Clinical pregnancy One or more observed gestational sac or definitive clinical signs of pregnancy under ultrasonography at 7 
weeks of gestation (including clinical documented ectopic pregnancy)
  Ongoing pregnancy Presence of a gestational sac and fetal heartbeat after 12 weeks of gestation
  Time to ongoing pregnancy 
leading to live birth*
Time from randomisation to detection of ongoing pregnancy after completion of the transfer
Maternal safety outcomes
  OHSS Exaggerated systemic response to ovarian stimulation characterised by a wide spectrum of clinical and 
laboratory manifestations. It is classified as mild, moderate, or severe according to the degree of abdominal 
distention, ovarian enlargement and respiratory haemodynamic, and metabolic complications. Diagnosed by 
ultrasound, blood testing and physical examination according the RCOG Guideline.21
  Miscarriage Spontaneous loss of an intra- uterine pregnancy prior to 28 completed weeks of gestational age
  Ectopic pregnancy A pregnancy outside the uterine cavity, diagnosed by ultrasound, surgical visualisation or histopathology
Obstetric and perinatal complications
  Gestational diabetes mellitus Development of diabetes during pregnancy
  Hypertensive disorders of 
pregnancy
Including pregnancy- induced hypertension, pre- eclampsia and eclampsia
  Antepartum haemorrhage Including placenta previa, placenta accreta and unexplained
  Birth weight Including low birth weight (weight <2500 g at birth), very low birth weight (<1500 g at birth), high birth weight 
(>4000 g at birth) and very high birth weight (>4500 g at birth)
  Large for gestational age A birth weight greater than the 90th centile of the sex- specific birth weight for a given gestational age 
reference
  Small for gestational age A birth weight less than the 10th centile for the sex- specific birth weight for a given gestational age 
reference
  Preterm birth Birth of a fetus delivered after 28 and before 37 completed weeks of gestational age in participants 
confirmed ongoing pregnancy
  Congenital anomaly Structural or functional disorders that occur during intrauterine life and can be identified prenatally, at 
birth or later in life, including trisomy 21 syndrome, neural tube defect, congenital heart disease, cleft lip, 
excessive numbers of fingers or toes, hydrocephalus.
  Perinatal mortality Fetal or neonatal death occurring during late pregnancy (at 28 completed weeks of gestational age and 
later), during childbirth, or up to seven completed days after birth)
*Only ongoing pregnancy leading to live birth within 6 months of the first oocyte retrieval cycle after randomisation will be counted.
(IVF) in terms of ongoing pregnancy leading to live birth. 
On the basis of actual data on the women with PCOS who 
underwent IVM or IVF- ET in our reproductive medi-
cine centre, we assume that after IVF the proportions of 
ongoing pregnancy leading to live birth for the PCOS 
women are 35% per transferred cycle.22 23 With a non- 
inferiority margin of 15%, power of 80% and one- sided 
α 0.025, we will need to enrol 159 participants in each 
group (the ratio between groups will be 1:1). Taking 
consideration of dropout rate as 10% (such as cancella-
tion during trial procedures), each group will include 175 
participants (a total of 350 participants).
Statistical analysis
The result will be analysed according to the intention- 
to- treat principle. Preprotocol (PP) analysis will also be 
conducted as a sensitivity analysis. Baseline characteristics 
will be described by descriptive analysis, and the balance 
among groups or subgroups will be assessed by analysis 
for different kinds of data. For continuous variables, 
the normality distribution will be estimated by using 
frequency histograms and the Kolmogorov- Smirnov test 
initially. If the continuous variables are normally distrib-
uted, they will be presented as means with SDs. If the 
continuous variables are non- normally distributed, their 
medians and inter- quantile ranges will be reported. 
For categorical variables, we will present the propor-
tion between each group. In addition, the recruitment 
numbers, those participants lost to follow- up, protocols 
violations and other relevant data will also be reported. 
A comparison between groups will be performed using 
the independent sample t- test, Mann- Whitney U test for 
continuous variables or Pearson’s χ2 test/Fisher’s exact 
test for categorical variables as appropriate. The primary 
outcome, ongoing pregnancy leading to live birth, will 
be compared using Pearson’s χ2 test or Fisher’s exact test 
as appropriate. Categorical secondary outcomes will be 
compared between two groups using a similar approach 
as the primary outcome. Student’s t- test or Wilcoxon test 
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will be used as appropriate for continuous secondary 
outcomes, such as birth weight and etc. The relative risks 
(RR) and absolute rate differences (ARD) and their 95% 
CI between the two groups will be calculated. And the 
95% CI of the ARDs will be used to evaluate if the experi-
mental group (IVM) is non- inferior to the control group 
(IVF- ET). For the time- to- event outcome, the Kaplan- 
Meier curve will be used. Multiple variable logistic regres-
sion models will be used to assess the treatment effect 
adjusting for other potential confounding variables that 
are unbalanced in the baseline.
Missing data will be treated as missing at random and 
will be imputed using the last observation carried forward 
method. For the missing values, a sensitivity analysis 
will be done under the hypothesis of the worst and the 
best outcomes for each missing individual. Therefore, 
all secondary outcomes will be considered exploratory. 
All statistical analyses will be done using the statistical 
package SPSS V.25.0 (SPSS). Statistical significance is 
defined as p<0.05 with two- sided testing except for the 
non- inferiority test for the primary outcome.
trIAl StAtuS
The study was designed in 2017. The first participant 
was recruited in March 2018 and the last participant 
was recruited in July 2019. The follow- up is ongoing. 
It is expected that data collection will be completed in 
October 2020.
PAtIEnt And PublIC InvolvEMEnt
This research was done without patient or public involve-
ment. Neither patients nor the public was involved in the 
development of the research question, study design or 
implementation of this trial. Patients will not be invited 
to develop patient- relevant outcomes or interpret the 
results, as well as the writing or editing of the final manu-
script for readability or accuracy. As interventions in our 
study are both routine procedures during clinical work, 
the burden of the intervention is assessed by patients 
themselves.
EthICS And dISSEMInAtIon
The trial had been reviewed and approved by the Science 
Research Ethics Committee of Peking University Third 
Hospital (2017sz-066). Informed consent will be obtained 
from each participant before randomisation. The 
researchers will permit trial- related monitoring, audits, 
regulatory inspections, providing direct access to source 
data and documents. There are no additional data avail-
able in this study protocol.
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